Page last updated: 2024-09-05

sorafenib and Hemangioendothelioma, Epithelioid

sorafenib has been researched along with Hemangioendothelioma, Epithelioid in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Baldi, GG; Leonard, H; Stacchiotti, S; Tap, W; Zaffaroni, N	1
Bay, JO; Blay, JY; Bompas, E; Chaigneau, L; Chevreau, C; Cioffi, A; Clisant, S; Fournier, C; Gauthier, E; Isambert, N; Italiano, A; Le Cesne, A; Penel, N; Ray-Coquard, I; Robin, YM	1
Bal-Mahieu, C; Baldeyrou, B; Bay, JO; Blay, JY; Bompas, E; Chevreau, C; Clisant, S; Fournier, C; Italiano, A; Lansiaux, A; Le Cesne, A; Penel, N; Piperno-Neumann, S; Ray-Coquard, I; Robin, YM	1

Reviews

1 review(s) available for sorafenib and Hemangioendothelioma, Epithelioid

Article	Year
New Molecular Insights, and the Role of Systemic Therapies and Collaboration for Treatment of Epithelioid Hemangioendothelioma (EHE). Current treatment options in oncology, 2023, Volume: 24, Issue:6 Topics: Hemangioendothelioma, Epithelioid; Humans; Prognosis; Retrospective Studies; Sarcoma; Sorafenib	2023

Trials

2 trial(s) available for sorafenib and Hemangioendothelioma, Epithelioid

Article	Year
Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO). Cancer, 2013, Jul-15, Volume: 119, Issue:14 Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; France; Head and Neck Neoplasms; Hemangioendothelioma, Epithelioid; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rare Diseases; Sorafenib; Time Factors; Treatment Outcome	2013
Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial. Targeted oncology, 2014, Volume: 9, Issue:3 Topics: Antineoplastic Agents; Biomarkers, Tumor; Enzyme-Linked Immunosorbent Assay; Hemangioendothelioma, Epithelioid; Hemangiosarcoma; Humans; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A	2014

Article

Year

Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO).

Cancer, 2013, Jul-15, Volume: 119, Issue:14

Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; France; Head and Neck Neoplasms; Hemangioendothelioma, Epithelioid; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rare Diseases; Sorafenib; Time Factors; Treatment Outcome

2013

Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial.

Targeted oncology, 2014, Volume: 9, Issue:3

Topics: Antineoplastic Agents; Biomarkers, Tumor; Enzyme-Linked Immunosorbent Assay; Hemangioendothelioma, Epithelioid; Hemangiosarcoma; Humans; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A

2014